Yungjin Pharm Ind. Co., Ltd. - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 41 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Markets Direct's, 'Yungjin Pharm Ind. Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Yungjin Pharm Ind. Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Yungjin Pharm Ind. Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Yungjin Pharm Ind. Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Yungjin Pharm Ind. Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Yungjin Pharm Ind. Co., Ltd.'s pipeline products

Reasons to buy

- Evaluate Yungjin Pharm Ind. Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Yungjin Pharm Ind. Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Yungjin Pharm Ind. Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Yungjin Pharm Ind. Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Yungjin Pharm Ind. Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Yungjin Pharm Ind. Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Yungjin Pharm Ind. Co., Ltd. Snapshot 6
Yungjin Pharm Ind. Co., Ltd. Overview 6
Key Information 6
Key Facts 6
Yungjin Pharm Ind. Co., Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
Yungjin Pharm Ind. Co., Ltd. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Yungjin Pharm Ind. Co., Ltd. - Pipeline Products Glance 15
Yungjin Pharm Ind. Co., Ltd. - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
Yungjin Pharm Ind. Co., Ltd. - Clinical Stage Pipeline Products 17
Phase I Products/Combination Treatment Modalities 17
Yungjin Pharm Ind. Co., Ltd. - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Yungjin Pharm Ind. Co., Ltd. - Drug Profiles 20
KTG-001 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
(acetaminophen + tramadol hydrochloride) SR 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
YBH-1603 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
YNP-1707 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
YOB-1604 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
YPL-001 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ceftaroline fosamil 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
YAR-1502 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
YHT-1808 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
YLS-1501 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
YPU-1705 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
YRA-1909 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
YGD-1710 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
YPE-1706 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Yungjin Pharm Ind. Co., Ltd. - Pipeline Analysis 34
Yungjin Pharm Ind. Co., Ltd. - Pipeline Products by Target 34
Yungjin Pharm Ind. Co., Ltd. - Pipeline Products by Route of Administration 35
Yungjin Pharm Ind. Co., Ltd. - Pipeline Products by Molecule Type 36
Yungjin Pharm Ind. Co., Ltd. - Pipeline Products by Mechanism of Action 37
Yungjin Pharm Ind. Co., Ltd. - Dormant Projects 38
Yungjin Pharm Ind. Co., Ltd. - Locations And Subsidiaries 39
Head Office 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Yungjin Pharm Ind. Co., Ltd., Key Information 6
Yungjin Pharm Ind. Co., Ltd., Key Facts 6
Yungjin Pharm Ind. Co., Ltd. - Pipeline by Indication, 2014 9
Yungjin Pharm Ind. Co., Ltd. - Pipeline by Stage of Development, 2014 10
Yungjin Pharm Ind. Co., Ltd. - Monotherapy Products in Pipeline, 2014 11
Yungjin Pharm Ind. Co., Ltd. - Combination Treatment Modalities in Pipeline, 2014 12
Yungjin Pharm Ind. Co., Ltd. - Partnered Products in Pipeline, 2014 13
Yungjin Pharm Ind. Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 14
Yungjin Pharm Ind. Co., Ltd. - Pre-Registration, 2014 15
Yungjin Pharm Ind. Co., Ltd. - Phase III, 2014 16
Yungjin Pharm Ind. Co., Ltd. - Phase I, 2014 17
Yungjin Pharm Ind. Co., Ltd. - Preclinical, 2014 18
Yungjin Pharm Ind. Co., Ltd. - Discovery, 2014 19
Yungjin Pharm Ind. Co., Ltd. - Pipeline by Target, 2014 34
Yungjin Pharm Ind. Co., Ltd. - Pipeline by Route of Administration, 2014 35
Yungjin Pharm Ind. Co., Ltd. - Pipeline by Molecule Type, 2014 36
Yungjin Pharm Ind. Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 37
Yungjin Pharm Ind. Co., Ltd. - Dormant Developmental Projects,2014 38